Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN-812 (Viloxazine Extended-Release) Pharmacokinetics in Healthy Adults.

导出 LinkOut

翻译打印收藏纠错

作者： Zhao,Wang ^[1] ; Alisa R,Kosheleff ^[1] ; Lilian W,Adeojo ^[1] ; Oyinkansola,Odebo ^[1] ; Toyin,Adewole ^[1] ; Peibing,Qin ^[1] ; Vladimir,Maletic ^[2] ; Stefan,Schwabe ^[1] ; Azmi,Nasser ^[1]

作者单位： Supernus Pharmaceuticals, Inc., Rockville, Maryland, USA. ^[1] Department of Psychiatry/Behavioral Science, University of South Carolina School of Medicine, Greenville, South Carolina, USA. ^[2]

关键词 CYP2D6 SPN-812 attention-deficit/hyperactivity disorder paroxetine pharmacokinetics viloxazine

主题词肾上腺素能摄取抑制剂(Adrenergic Uptake Inhibitors);成年人(Adult);注意力缺陷障碍伴多动(Attention Deficit Disorder with Hyperactivity);迟效制剂(Delayed-Action Preparations);女(雌)性(Female);人类(Humans);男(雄)性(Male);中年人(Middle Aged);帕罗西汀(Paroxetine);维洛沙秦(Viloxazine)

DOI 10.1002/cpdd.948

PMID 33943033

发布时间 2022-03-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Clinical pharmacology in drug development

2021年10卷11期

1365-1374页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN-812 (Viloxazine Extended-Release) Pharmacokinetics in Healthy Adults.

Clinical pharmacology in drug development

相似文献

Clinical pharmacology in drug development

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN-812 (Viloxazine Extended-Release) Pharmacokinetics in Healthy Adults.

Clinical pharmacology in drug development

相似文献

Clinical pharmacology in drug development

相关期刊

检索历史清除